Search Results for ""

During two March 2023 focus group discussions, 14 oncology nurses shared their experiences with caring for patients receiving CAR T-cell therapy in hematologic malignancies. The discussions were conducted to help ONS identify and assess the key nursing issues, trends, and barriers related to the use of CAR T-cell therapy in hematologic malignancies and identify strategies to support oncology nurses in clinical practice. 

“Being an ally means you’re coming from a place where you know what issues are going on, you stay up to date about what’s happening in the world, and just because you don’t identify as part of the LGBTQIA+ community, doesn’t mean that you can’t teach about what’s going on,” Beau Amaya, MSN, RN, OCN^®, associate director of patient and caregiver education at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS^®, oncology clinical specialist at ONS. Amaya discussed the nursing considerations when caring for LGBTQ+ patients with cancer.

Cancer is an epidemic, and health systems around the world are waging the fight against it every minute of every day. Oncology nurses are at the forefront of that battle, delivering care, carrying out clinical trials, and advancing research to translate into evidence-based practice. Join ONS and be part of the community dedicated to transforming cancer care.   

ONS membership connects you with the expert-driven support and resources you need to provide essential, quality care to your patients. 

“I think it’s important to ensure that you consider each person uniquely. Because no matter how much I know or the nurse knows about the population, everybody is a little bit different. It’s really important to personalize every approach and ask them what they know and meet them where they are,” ONS member Reneé Kurz, DNP, RN, FNP-BC, AOCNP^®, director of clinical research operations at Rutgers Cancer Institute of New Jersey in New Brunswick, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS^®, oncology clinical specialist at ONS, during a conversation about increasing diversity in clinical trials.

Plant alkaloids are cell cycle–specific (including the S, late G2, and mitosis phases of division) antitumor agents that are derived from plants. They primarily interfere with microtubule function, preventing cell division. Review this huddle card in a group or individually to learn more about plant alkaloids.   

If you are involved in direct patient care, you don’t want to miss ONS Bridge™. This must-attend virtual event provides you with the latest information on care coordination and updates in therapy, hitting on the topics that affect you and your patients. Learn about the sessions offered during ONS's third annual virtual conference.

“I think there’s a big misconception that health literacy means someone’s ability to read or write, and really it’s much more than that,” ONS member Regina Carlisle, MS, BSN, RN, OCN^®, senior cancer information nurse at University Hospitals Seidman Cancer Center in Cleveland, OH, and member of the Cleveland ONS Chapter, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS^®, oncology clinical specialist at ONS. Carlisle discussed developing and providing patient education across various formats for patients with limited English proficiency.

The 48th Annual ONS Congress lived up to its theme: I left San Antonio, TX, on April 30 feeling rejuvenated, refocused, and revitalized. The conference sessions captured current challenges, and speakers shared strategies to implement their information into practice. Attendees learned about a broad spectrum of topics through the invited sessions, oral abstract podium presentations, poster presentations, and industry events.   

Macy is a 57-year-old patient with a history of hormone receptor–positive invasive ductal carcinoma of the right breast, diagnosed in 2017. She achieved complete remission after chemotherapy with anthracycline plus paclitaxel followed by bilateral mastectomy with reconstruction in 2018.

For nearly 2,500 years, nonmaleficence, or “do no harm,” has been a fundamental tenet of medical ethics. Yet none of today’s U.S. breast, cervical, colorectal, lung, or prostate cancer screening guidelines report all of the harms associated with screening tests, researchers said in study results published in Annals of Internal Medicine.